Prognostic significance of 18FDG PET/CT in colorectal cancer patients with liver metastases: a meta-analysis

Xin, Qian; Li, Jianjun; Wu, Cheng; Song, Shaoli; Tong, Linjun; Huang, Gang; Feng, Yuanbo; Jiang, Yansheng; Liu, Yewei; Yin, Ting; Ni, Yicheng

doi:10.1186/s40644-015-0055-z

Cited by 72 publications

(47 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this meta-analysis, STATA statistics software (Version 12.0) and RevMan 5.3 software were used to calculate the pooled hazard ratios (HRs) and odds ratios (ORs) with their 95% CIs, respectively. DFS, PFS, and RFS were merged as event-free survival (EFS) [18,19]. Statistical heterogeneity was evaluated by the Q-statistic test and I 2 statistic test, and two different models were selected according to the heterogeneity level; if there was significant heterogeneity (P Q < 0.1 or/and I 2 >50%), then the randomeffects model was used; otherwise, the fixed-effects model was applied for nonsignificant heterogeneity.…”

Section: Discussionmentioning

confidence: 99%

Calpain Small Subunit 1 Protein in the Prognosis of Cancer Survivors and Its Clinicopathological Correlation

Tang

Yin

Liu

et al. 2019

BioMed Research International

View full text Add to dashboard Cite

Background/Aims. Calpain small subunit 1 (Capn4) is implicated in tumorigenesis and plays a key role in multiple tumors. This study aimed to fully illustrate the prognostic value of Capn4 protein in cancer patients. Methods. A systematic search was conducted against several online databases. Hazard ratios (HRs) or odds ratio (ORs) were used to investigate the relationship between Capn4 protein expression and prognosis as well as clinical parameters in cancer survivors. Results. Eleven studies involving 1775 patients were identified. Overall, the results showed that Capn4 protein was associated with poor prognosis of overall survival (OS) (HR=1.74; 95% CI:1.47-2.01; p<0.001) and event-free survival (EFS) (HR=1.73; 95% CI:1.39-2.07; p<0.001) in various cancers. And expression of Capn4 protein was related to depth of invasion (OR= 4.17; 95% CI: 1.42-12.27; p=0.01), venous invasion (OR=2.34; 95% CI: 1.07-5.13; p=0.03), lymph node metastasis (2.74; 95% CI: 1.98-3.79; p<0.001), distant metastasis (OR=4.02; 95% CI: 2.14-7.57; p<0.001), and clinical stage (OR=2.87; 95% CI: 1.94-4.26; p<0.001), whereas expression of the Capn4 protein was not associated with gender (OR=1.09; 95% CI: 0.86-1.39; p=0.47) and tumor differentiation (OR=1.16; 95% CI: 0.90-2.23; p=0.25). Conclusions. Expression of Capn4 protein is associated with cancer survival and clinicopathologic characteristics in patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Calpain Small Subunit 1 Protein in the Prognosis of Cancer Survivors and Its Clinicopathological Correlation

Tang

Yin

Liu

et al. 2019

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…In addition, other reports have indicated that SUV reflects the therapeutic effect after chemotherapy . Furthermore, Xia et al reviewed the application of FDG‐PET and found that SUV was correlated with prognosis after treatment in 867 cases of CRLM from 15 studies. Although most of these reports have indicated that SUV is related to prognosis after chemotherapy, a few retrospective studies have revealed that SUV is related to the postoperative prognosis of CRLM.…”

Section: Discussionmentioning

confidence: 99%

A new strategy based on fluorodeoxyglucose‐positron emission tomography for managing liver metastasis from colorectal cancer

Watanabe

Harimoto

Araki

et al. 2018

Journal of Surgical Oncology

View full text Add to dashboard Cite

Background Prognostic models are needed to manage liver metastasis from colorectal cancer (CRLM). Thus, we developed an algorithm to guide treatment based on the standardized uptake value (SUV) from fluorodeoxyglucose‐positron emission tomography (FDG‐PET). Methods We retrospectively evaluated 148 patients who underwent surgery for CRLM, including 107 cases of primary surgery and 41 cases with preoperative chemotherapy before conversion surgery. We evaluated the prognostic value of perioperative SUV among primary surgery cases, as well as the prognostic value of the SUV change ratio after conversion surgery (postchemotherapy/prechemotherapy SUV). Results In the primary surgery group, recurrence‐free survival (RFS) was independently predicted by an SUV of ≥6.04 (P = 0.042) and ≥4 liver metastases ( P = 0.003). The combination of an SUV of ≥6.04 and ≥4 liver metastases was strongly associated with poor RFS ( P < 0.001). In the conversion surgery group, the SUV change ratio was associated with tumor size change and pathological response. An SUV change ratio of ≥0.293 was associated with shorter RFS ( P = 0.006) and independently predicted RFS ( P = 0.026). We established a therapeutic algorithm for managing CRLM based on these results. Conclusion FDG‐PET may be useful for predicting recurrence and prognosis in cases of CRLM, and our algorithm may be useful for managing multiple CRLMs.

show abstract

“…72,73 In patients with liver metastases treated with chemotherapy, reduction in FDG-uptake indicates improved prognosis. 74 As yet there is no threshold to allow decision-making based on these data, but novel methods for analyzing PET data may further improve prognostication using this functional imaging tool. 75…”

Section: Metabolic Imagingmentioning

confidence: 99%

Imaging oligometastatic cancer before local treatment

Franklin

Sharma

Harris

et al. 2016

The Lancet Oncology

View full text Add to dashboard Cite

With the advent of novel treatment strategies to help widen the therapeutic window for patients with oligometastatic cancer, improved biomarkers are needed to reliably define patients who can benefit from these treatments. Multimodal imaging is one such option and should be optimised to comprehensively assess metastatic sites, disease burden, and response to neoadjuvant treatment in each disease setting. These features will probably remain important prognostic biomarkers, and are crucial in planning multidisciplinary treatment. There are opportunities to extract additional phenotypic information from conventional imaging, while novel imaging techniques can also reveal specific aspects of tumour biology. Imaging can both characterise and localise the phenotypic heterogeneity of multiple tumour sites. Novel approaches to existing imaging datasets and correlation with tumour biology will be important in realising the potential of imaging to guide treatment in the oligometastatic setting. In this Personal View, we discuss the current status and future directions of imaging before treatment in patients with extracranial oligometastases.

show abstract

Prognostic significance of 18FDG PET/CT in colorectal cancer patients with liver metastases: a meta-analysis

Cited by 72 publications

References 38 publications

Calpain Small Subunit 1 Protein in the Prognosis of Cancer Survivors and Its Clinicopathological Correlation

Calpain Small Subunit 1 Protein in the Prognosis of Cancer Survivors and Its Clinicopathological Correlation

A new strategy based on fluorodeoxyglucose‐positron emission tomography for managing liver metastasis from colorectal cancer

Imaging oligometastatic cancer before local treatment

Contact Info

Product

Resources

About